A Study to Find a Suitable Dose of Exl-111 for Further Research

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose trial of Exl-111 in healthy participants. The trials consists of 2 parts, as follows: Part A (SAD): Up to 5 dose cohorts, each with 8 participants, randomized into 2 arms: Exl-111 and placebo. Part B (MAD): Up to 3 dose cohorts, each with 10 participants, randomized into 3 arms: Exl-111, placebo, and an active comparator (omalizumab).

NCT Number	NCT07356713
Lead Sponsor	Excellergy Inc.
Conditions	Allergic Disease
Enrollment	70 participants
Start Date	2026-01-08
Primary Completion	2026-12-07 (estimated)
Study Completion	2026-12-07 (estimated)
Updated on ClinicalTrials.gov	2026-02-19